QTRX trades 5.1% above Wall Street's consensus target of $3.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes QTRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 10 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Quanterix Corporation (QTRX) has a Wall Street consensus price target of $3.00, based on estimates from 10 covering analysts. With the stock currently trading at $3.16, this represents a potential downside of -5.1%. The company has a market capitalization of $149M.
Analyst price targets range from a low of $3.00 to a high of $3.00, representing a 0% spread in expectations. The median target of $3.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, QTRX trades at a trailing P/E of -1.3x. Analysts expect EPS to grow +14.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SEERSeer, Inc. | $99M | $1.80 | $4.00 | +122.2% | Hold | — | 4 |
 CDNACareDx, Inc | $2.8B | $54.31 | $58.75 | +8.2% | Buy | 45.1x | 13 |
 NTRANatera, Inc. | $56.0B | $390.79 | $335.07 | -14.3% | Buy | — | 28 |
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
 BIOBio-Rad Laboratories, Inc. | $10.2B | $378.88 | $350.00 | -7.6% | Buy | 39.3x | 14 |
 MESOMesoblast Limited | $2.0B | $15.29 | $39.00 | +155.1% | Buy | — | 11 |
 ABCLAbCellera Biologics Inc. | $3.8B | $12.31 | $15.33 | +24.5% | Buy | — | 12 |
 FLGTFulgent Genetics, Inc. | $604M | $21.27 | $19.00 | -10.7% | Buy | — | 9 |
 PACBPacific Biosciences of California, Inc. | $438M | $1.41 | $1.18 | -16.3% | Buy | — | 18 |
 TMOThermo Fisher Scientific Inc. | $247.2B | $665.30 | $623.36 | -6.3% | Buy | 26.5x | 43 |
Quick answers to the most common questions about buying QTRX stock.
Wall Street's consensus price target for QTRX is $3, -5.1% from its current price of $3.16. The below-market target from 10 analysts suggests limited near-term appreciation.
QTRX has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $3 implies -5.1% downside from current levels.
QTRX's current price is $3.16 with a consensus target of $3 (-5.1% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $3 for QTRX, while the most conservative target is $3. The consensus of $3 represents the median expectation. These targets typically reflect 12-month expectations.
QTRX is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month QTRX stock forecast based on 10 Wall Street analysts shows a consensus price target of $3, with estimates ranging from $3 (bear case) to $3 (bull case). The median consensus rating is "Buy".
Analysts are cautious on QTRX, with 0 Sell ratings and a price target of $3 (-5.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
QTRX analyst price targets range from $3 to $3, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.